Aeterna Zentaris Inc.

Equities

AEZS

CA0079756007

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 01:55:39 2024-07-04 pm EDT			5-day change	1st Jan Change
5.99 ^CAD	+0.50%		+1.53%	-41.73%

Jul. 02	Mannatech Names James Clavijo Finance Chief	MT
Jun. 13	Aeterna Zentaris Inc. Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	CI

Aeterna Zentaris Inc. Announces Departure of Interim Chief Financial Officer, Jeffrey Whitnell

December 08, 2017 at 08:07 am EST

Aeterna Zentaris Inc. announced the departure of the company's Interim Chief Financial Officer, Jeffrey Whitnell, effective December 7, 2017. The company is currently reviewing its resource requirements with respect to its finance department and has commenced a search for Mr. Whitnell's replacement as principal financial officer.

Latest news about Aeterna Zentaris Inc.

Mannatech Names James Clavijo Finance Chief	Jul. 02	MT
Aeterna Zentaris Inc. Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	Jun. 13	CI
Aeterna and Ceapro Brief: Cos Complete Merger Transaction; New Name Expected to be Announced in Coming Weeks and Details of AGM Expected to be Announced Shortly	Jun. 03	MT
Aeterna Zentaris Inc. completed the acquisition of Ceapro Inc. in a merger of equals transaction.	Jun. 02	CI
Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	May. 29	MT
Aeterna Zentaris Finalizes Some Details for Ceapro Merger	May. 17	MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	May. 17	MT
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden	May. 14	MT
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	Mar. 28	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	Mar. 28	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	Mar. 27	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	Mar. 27	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	Mar. 27	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	Feb. 26	MT
Traders Search for Fresh Cues After Fed-Driven Rally as US Equity Futures Waver Pre-Bell	Dec. 18	MT
Top Premarket Gainers	Dec. 18	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	Dec. 14	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	Dec. 14	MT
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	Nov. 16	DJ
HC Wainwright Cuts Aeterna Zentaris' Price Target to $15 From $28, Maintains Buy Rating	Nov. 13	MT

Chart Aeterna Zentaris Inc.

Duration

Period

More charts

Company Profile

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.

Sector

Biotechnology & Medical Research

Calendar

2024-07-16 - Annual General Meeting

More about the company

	1st Jan change	Capi.
AETERNA ZENTARIS INC.	-41.73%	13.47M
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+42.44%	40.03B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research